How to Cite
Abstract
Aim. Allele frequency and genotype distribution in the cervical cancer group were compared with those of the control group to determine whether polymorphism Arg72Pro of Р53 gene elevates the susceptibility of Kyrgyz women to cervical cancer (CC).
Materials and Methods. A total of 102 women (mean age 53,5±10 years) of Kyrgyz nationality with cervical cancer were recruited into the study and 102 healthy women were used as the control group (mean age 46,5±8,5 years). The diagnosis of cervical cancer was confirmed histologically. 88 % (90/102) of women with cervical cancer were human papillomavirus (HPV) positive. 17 % (15/90) specimens were positive for HPV type 16, 48 % (43/90) were positive for HPV type 18 and 35 % (32/90) were positive both HPV - 16/18. Presence of human papillomavirus DNA types 16 and 18 was analyzed by polymerase chain reaction with hybridization-fluorescence detection. The Arg72Pro polymorphisms of the P53 gene were determined by the PCR-RFLP method.
Results. No significant difference was found between genotype distributions in the cervical cancer patients and the control group (χ2=1,24; р=0,54). However, the Arg72Arg genotype and Arg72 allele was significantly more frequent in women with cervical cancers infected with HPV than in the control group (χ2=7,25; р=0,027 for для genotype, χ2=6,83; р=0,009 for allele). Women who are HIV positive and having the Arg72 allele had 1,94 fold (OR=1,94 [1,20-3,15]; р=0,009) higher risk of developing CC compared with subjects carrying neither of these alleles. HPV positive women carrying the genotype Arg72Arg had 1,85 fold (OR=1,85 [1,03-3,32]; р=0,027) higher risk of CC.
Conclusion. The Arg72Arg genotype of р53 gene in HIV positive women from Kyrgyz Republic may represent a potential risk factor for the development of cervical cancer.
References
Измайлова З.М., Макимбетов Э.К. Некоторые аспекты дескриптивной эпидемиологии при раке шейки матки у женщин в Кыргызской республике // Вестник КРСУ. - 2014. - Т. 14 (10). - С. 121-124.
Сметанникова Н.А., Сметанникова М.А., Белявская В.А. и др. Опухолеассоциированный полиморфизм 72-го кодона гена р53: данные исследования долгожителей Новосибирской и Тюменской областей и мета-анализа // Сибирский Онкологический Журнал. - 2004. - Т. 2/3. - С. 124-129.
Arbel-Alon S., Menczer J., Feldman N. et al. Codon 72 polymorphism of p53 in Israeli Jewish cervical cancer patients and healthy women // Int. J. Gynecol. Cancer. - 2002. - Vol. 12. - P. 741-744.
Brenna S.M., Silva I.D., Zeferino L.C. et al. Prevalence of codon 72 P53 polymorphism in Brazilian women with cervix cancer // Genetics and Molecular Biology. - 2004. - Vol. 27 (4). - P 496-499.
Bruni L., Barrionuevo-Rosas L., Albero G. Human Papillomavirus and Related Diseases in the World // Summary Report. - 2016-02-25.
Ciotti M., Coletti A., Giuliani L. et al. The p53 codon 72 arg/arg homozygous women in central Italy are at increased risk for HPV infections // Anticancer Res. - 2006. - Vol. 26. - P. 3745-3748.
Dumont Patrick., I-Ju Leu., Anthony C. et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential // Nature Genetics. - 2003. - Vol. 33. - P. 357-365.
George Ph. P53 How crucial its role in cancer? // Int. J. Curr. Pharm. Res. - 2011. - Vol. 31 (2). - P. 1925.
Gudleviciene Z., Didziapetriene J., Ramael M. et. Human papillomavirus and p53 polymorphismin Lithuanian cervical cancer patients // Gynecol. Oncol. - 2006. - Vol. 102. - P. 530-533.
Jee S.H., Won SY, Yun J.E. et al. Polymorphism p53 codon- 72 and invasive cervical cancer: a meta- analysis // Int. J. Gynaecol. Obstet.- 2004. - Vol. 85. - P. 301308.
Katiyar S., Thelma B.K., Murthy N.S. et al. Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India // Mol Cell Biochem. - 2003. - Vol. 252 (1-2). - P 117-124.
Kim J.W., Roh J.W., Park N.H. et al. Polymorphism of TP53 codon 72 and the risk of cervical cancer among Korean women // Am J. Obstet. Gynecol. - 2001. - Vol. 184. - P. 55-58.
Malcolm E.K., Baber G.B., Boyd J.C., Stoler M.H. Polymorphism at codon 72 of p53 is not associated with cervical cancer risk // Modern Pathol. - 2000. - Vol. 13. - P. 373-378.
Matlashewski G.J., Tuck S., Pim D. et al. Primary structure polymorphism at amino acid residue 72 of human p53 // Mol Cell Biol. - 1987. - Vol. 7 (2). - P. 961-963.
Min-min H., Mingrong X., Zeyi C. et al. Analysis of p53 codon 72 polymorphism and its association with human papillomavirus 16 and 18 E6 in Chinese cervical lesions // Int. J. Gynecol. Cancer. - 2006. - Vol. 16. - P 2004-2008.
Nishikawa A., Fugimoto T., Akutagawa N. et al. P53 polymorphism (codon-72) has no correlation with the development and the clinical features of cervical cancer // Int. J. Gynecol. Cancer. - 2000. - Vol. 10. - P. 402407.
Ojeda J.M., Ampuero S., Rojas P et al. p53 codon 72 polymorphism and risk of cervical cancer // Biol. Res. - 2003. - Vol. 36. - P. 279-283.
Pegoraro R.J., Rom L., Lanning A. et al. p53 codon 72 polymorphism and human papillomavirus type in relation to cervical cancer in South African women // Int. J. Gynecol. Cancer. - 2002. - Vol. 12. - P. 383-388.
Rosenthal A.N., Ryan A., Al-Jehani R.M. et al. P53 codon 72 polymorphism and risk of cervical cancer in UK // Lancet. - 1998. - Vol. 352. - P. 871-872.
Saranth D., Khan Z., Tandle A.T. et al. HPV 16 /18 prevalence in cervical lesions/ cancers and p 53 genotypes in cervical cancer patients in India // Gynecol. Oncol. - 2002. - Vol. 86. - P. 157-162.
Storey A., Thomas M., Kalita A. et al. Role of p53 polymorphism in the development of human papillomavirus-associated cancer // Nature. - 1998. - Vol. 393. - P. 229-234.
Thomas M., Pim D., Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV // Oncogene. - 1999. - Vol. 18. - P. 7690-7700.
World Cancer Report. World Health Organization. - 2014. pp. Chapter 5.12.
Zehbe I., Voglino G., Wilander E. et al. P53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development // Cancer Res. - 2001. - Vol. 61. - P. 608-611.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2017